Bioline RX Ltd Sponsored ADR AI Stock Analysis
Want to see BLRX full AI Analyst Report?
Bioline RX Ltd Sponsored ADR (BLRX) AI Stock Analysis
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
BLRX scores low primarily due to very weak financial performance (large losses, declining revenue, and ongoing cash burn) and strongly bearish technicals with the stock far below key moving averages. The latest earnings call adds some support via encouraging GLIX1 progress and a stated cash runway into 1H27, but negative earnings and limited valuation support (negative P/E, no dividend) keep the overall score subdued.
Bioline RX Ltd Sponsored ADR (BLRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 17.66K
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 1.35
- Revenue Growth
- -91.94%
- EPS Growth
- 55.29%
- Country
- US
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company Description
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully...
How the Company Makes Money
BiolineRx makes money primarily through commercialization-related revenue from its approved product APHEXDA (motixafortide), where revenue is generated from product sales (directly and/or via commercial partners, depending on territory and distributi...
Bioline RX Ltd Sponsored ADR Earnings Call Summary
The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.
Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
Financials are very weak: deeply negative profitability (net margin about -572%), shrinking TTM revenue (~-35%), and continued cash burn (TTM operating/free cash flow roughly -$10.9M). The balance sheet leverage is moderate for biotech (debt-to-equity ~0.58, improving vs. 2024), but negative ROE (~-47%) and ongoing losses keep overall financial strength low.
Income Statement
22NegativeBalance Sheet
46NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.40M | 1.19M | 28.94M | 4.80M | 0 | 0 |
| Gross Profit | 976.26K | 430.39K | 19.68M | 1.11M | 0 | 0 |
| EBITDA | -8.26M | -224.77K | 3.92M | -57.09M | -22.14M | -25.37M |
| Net Income | -8.03M | -1.18M | -9.22M | -60.61M | -24.95M | -27.05M |
Balance Sheet | ||||||
| Total Assets | 33.48M | 40.90M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 13.08M | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 7.94M | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 16.86M | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 13.77M | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | ||||||
| Free Cash Flow | -10.90M | -8.16M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -10.88M | -8.14M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | 12.45M | -8.61M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | -4.51M | 8.95M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 1.80, below the 50-day MA of 2.14, and below the 200-day MA of 2.66, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 11.61 is Positive, neither overbought nor oversold. The STOCH value of 0.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksBioline RX Ltd Sponsored ADR Peers Comparison
Overall Rating
AEON45Neutral
BLRX44Neutral
CTXR43Neutral
GTBP43Neutral
DARE41Neutral
KALA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $8.31M | -0.04 | 204.18% | ― | ― | 35.03% | |
| 44Neutral | $9.21M | -0.99 | -47.22% | ― | -91.94% | 55.29% | |
| 43Neutral | $14.48M | -0.25 | -67.15% | ― | ― | 57.48% | |
| 43Neutral | $7.29M | -0.03 | -443.08% | ― | ― | 75.09% | |
| 41Neutral | $11.49M | -0.77 | -748.08% | ― | ― | ― | |
| 41Neutral | $2.47M | -0.00 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BLRX | Bioline RX Ltd Sponsored ADR | 1.15 | -2.06 | -64.17% | |
| DARE | Daré Bioscience | 0.58 | -1.20 | -67.19% | |
| GTBP | Gt Biopharma, Inc. | 3.54 | -12.85 | -78.43% | |
| KALA | Kala Bio, Inc. | 3.83 | -1029.37 | -99.63% | |
| CTXR | Citius Pharma | 0.53 | -0.54 | -50.75% | |
| AEON | Aeon Biopharma, Inc. | 0.14 | -0.82 | -85.42% |
Bioline RX Ltd Sponsored ADR Corporate Events
BioLineRx Presents GLIX1 Clinical and Preclinical Data at SNO 2026
BioLineRx is a clinical-stage biopharmaceutical company pursuing therapies in oncology and rare diseases, with GLIX1 as its lead development asset and APHEXDA as its approved product for stem-cell mobilization in multiple myeloma. On November 16, 202...
BioLineRx and Hemispherian Report GLIX1–PARP Inhibitor Synergy in HR-Proficient Ovarian Cancer
On October 23, 2026, BioLineRx and Hemispherian reported preclinical data presented at the ESMO 2026 congress showing that GLIX1 synergizes with multiple PARP inhibitors across homologous recombination-proficient ovarian cancer cell lines, with high...
BioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGM
BioLineRx Ltd. held its Annual General Meeting of Shareholders on September 23, 2026, in Israel, where investors approved all proposals presented in the proxy materials. The meeting’s decisions reinforce the current board structure, capital framework...
BioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 2026
On September 10, 2026, BioLineRx and Hemispherian announced that two abstracts on their lead asset GLIX1 were accepted for presentation at the European Association of Neuro-Oncology’s 2026 meeting in Rome. One mini-oral session will highlight preclin...
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal
On August 27, 2026, BioLineRx entered into a securities purchase agreement for a registered direct offering of 480,696 ADSs and pre-funded warrants for up to 868,225 ADSs, alongside a concurrent private placement of unregistered warrants for up to 2,...
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results
BioLineRx reported unaudited financial results for the quarter ended June 30, 2026, on August 31, 2026, highlighting a net loss of $4.3 million on revenues of $0.3 million, increased R&D spending driven by its GLIX1 program, and cash and deposits of...
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases with lead asset GLIX1 in glioblastoma and its approved stem cell mobilization drug APHEXDA for multiple myeloma, continues to advance its pipeline t...
BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards
BioLineRx Ltd. reported on August 18, 2026 that it has called its Annual General Meeting of shareholders for September 23, 2026 at its Modi’in headquarters in Israel, with record date set at August 24, 2026 for holders of ordinary shares and American...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
